NASDAQ:TOCA - Tocagen Stock Price, Price Target & More

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen (NASDAQ:TOCA) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. Tocagen had a negative return on equity of 57.09% and a negative net margin of 109,579.49%. View Tocagen's Earnings History.

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Tocagen.

2 Wall Street analysts have issued twelve-month price objectives for Tocagen's shares. Their predictions range from $15.00 to $24.00. On average, they anticipate Tocagen's stock price to reach $19.50 in the next year. View Analyst Ratings for Tocagen.

Some companies that are related to Tocagen include NuCana (NCNA), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Rigel Pharmaceuticals (RIGL), Five Prime Therapeutics (FPRX), Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Aclaris Therapeutics (ACRS), BeyondSpring (BYSI), Lannett (LCI), Geron (GERN) and Prothena (PRTA).

(TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

News headlines about TOCA stock have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tocagen earned a news impact score of 0.01 on Accern's scale. They also assigned press coverage about the company an impact score of 45.81 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Tocagen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (2.86%), BVF Inc. IL (2.53%), Northern Trust Corp (0.91%), Russell Investments Group Ltd. (0.41%), Victory Capital Management Inc. (0.24%) and Millennium Management LLC (0.17%). Company insiders that own Tocagen stock include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Institutional Ownership Trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, JPMorgan Chase & Co., Northern Trust Corp and Victory Capital Management Inc.. View Insider Buying and Selling for Tocagen.

TOCA stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC and Rhumbline Advisers. Company insiders that have bought Tocagen stock in the last two years include Asha Das, Harry E Gruber, Mark G Foletta and Paul Schimmel. View Insider Buying and Selling for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $9.44.

Tocagen has a market capitalization of $187.97 million and generates $40,000.00 in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Tocagen employs 67 workers across the globe.

Tocagen's mailing address is 3030 BUNKER HILL STREET SUITE 230, SAN DIEGO CA, 92109. The company can be reached via phone at 858-412-8400 or via email at [email protected]